Overview
- In two Phase III real-world boat studies with 681 participants, Nereus cut vomiting rates to about 10%–20% versus roughly 38%–44% on placebo, with strong statistical significance.
- Nereus is an oral neurokinin‑1 receptor antagonist that targets substance P, a mediator of nausea and vomiting.
- Common adverse reactions reported in trials included somnolence (6%–12%) and fatigue (6%–8%).
- The FDA lifted a 2018 partial clinical hold on December 4 after reclassifying motion sickness as an acute condition, clearing the path to approval.
- Vanda expects a U.S. launch in the coming months, and its shares rose about 20% in after-hours trading following the announcement.